Tourmaline Bio

News

Novartis has bulked up in cardiology with a $1.4bn takeover of Tourmaline Bio and its drug for atherosclerotic cardiovascular disease (ASCVD).

News

In today's second sizeable M&A deal, Biogen has agreed to buy Apellis for around $5.6 billion, building on its aspirations in nephrology.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.